Prolong Pharmaceuticals

Name: Prolong Pharmaceuticals
Address: 300 Corporate Court, South Plainfield, New Jersey, United States, 07080, South Plainfield
Telephone: '+1 908-444-4660

South Plainfieldpharmaceuticals

About

Prolong Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company based in South Plainfield, New Jersey, founded in 2002. The company focuses on developing innovative treatments for central nervous system, hematology, and respiratory disorders, particularly addressing unmet needs in conditions such as ischemia and hypoxia related to stroke, sickle cell disease, and cystic fibrosis. Prolong's lead candidate, PP-007 (Sanguinate®), is a PEGylated multifunctional oxygen transfer agent designed to deliver oxygen to hypoxic tissues and improve perfusion while reducing inflammation. This product is currently ready for Phase 3 trials targeting acute ischemic stroke and vaso-occlusive crisis in sickle cell disease. The company also has a pipeline that includes a recombinant erythropoietin receptor agonist for anemia, among other candidates. Prolong employs around 105 people and has reported revenue of $35.2 million, having raised $30 million in funding.